John D. Iuliucci

1.4k total citations
16 papers, 637 citations indexed

About

John D. Iuliucci is a scholar working on Molecular Biology, Oncology and Hematology. According to data from OpenAlex, John D. Iuliucci has authored 16 papers receiving a total of 637 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 6 papers in Oncology and 6 papers in Hematology. Recurrent topics in John D. Iuliucci's work include Virus-based gene therapy research (3 papers), Bone health and treatments (3 papers) and Chronic Myeloid Leukemia Treatments (3 papers). John D. Iuliucci is often cited by papers focused on Virus-based gene therapy research (3 papers), Bone health and treatments (3 papers) and Chronic Myeloid Leukemia Treatments (3 papers). John D. Iuliucci collaborates with scholars based in United States and United Kingdom. John D. Iuliucci's co-authors include David C. Dalgarno, Tim Clackson, Tomi K. Sawyer, Brendan F. Boyce, Victor M. Rivera, William C. Shakespeare, Janet Ward, Chris Ward, Stuart Oliver and Scott Wardwell and has published in prestigious journals such as Journal of Clinical Investigation, Blood and Clinical Cancer Research.

In The Last Decade

John D. Iuliucci

16 papers receiving 602 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
John D. Iuliucci United States	13	316	212	122	119	95	16	637
Raymond D. Pastore United States	6	545 1.7×	216 1.0×	52 0.4×	54 0.5×	86 0.9×	11	768
Natalie Stickel Germany	9	259 0.8×	95 0.4×	79 0.6×	38 0.3×	184 1.9×	11	550
Jillian Harrison United States	13	266 0.8×	200 0.9×	176 1.4×	71 0.6×	103 1.1×	19	662
Matthew F. Leeman United Kingdom	9	240 0.8×	277 1.3×	63 0.5×	39 0.3×	45 0.5×	12	704
Yu Oyama Japan	15	106 0.3×	171 0.8×	178 1.5×	71 0.6×	120 1.3×	41	753
Akiko Izawa Japan	11	250 0.8×	132 0.6×	34 0.3×	40 0.3×	169 1.8×	16	537
Kirsten Kübler Germany	15	344 1.1×	339 1.6×	47 0.4×	79 0.7×	276 2.9×	27	924
Tatjana M.H. Niers Netherlands	10	195 0.6×	126 0.6×	138 1.1×	17 0.1×	58 0.6×	11	596
Tímea Besenyei Hungary	10	225 0.7×	126 0.6×	88 0.7×	40 0.3×	235 2.5×	12	753
R. Serafini Italy	13	474 1.5×	239 1.1×	198 1.6×	98 0.8×	91 1.0×	29	888

Countries citing papers authored by John D. Iuliucci

Since Specialization

Citations

This map shows the geographic impact of John D. Iuliucci's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John D. Iuliucci with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John D. Iuliucci more than expected).

Fields of papers citing papers by John D. Iuliucci

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John D. Iuliucci. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John D. Iuliucci. The network helps show where John D. Iuliucci may publish in the future.

Co-authorship network of co-authors of John D. Iuliucci

This figure shows the co-authorship network connecting the top 25 collaborators of John D. Iuliucci. A scholar is included among the top collaborators of John D. Iuliucci based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John D. Iuliucci. John D. Iuliucci is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Rivera, Victor M., Rachel M. Squillace, David F. Miller, et al.. (2011). Ridaforolimus (AP23573; MK-8669), a Potent mTOR Inhibitor, Has Broad Antitumor Activity and Can Be Optimally Administered Using Intermittent Dosing Regimens. Molecular Cancer Therapeutics. 10(6). 1059–1071. 87 indexed citations

Rivera, Victor M., Qihong Xu, Frank Wang, et al.. (2007). Potent Antitumor Activity of AP24534, an Orally Active Inhibitor of Bcr-Abl Variants Including T315I, in In Vitro and In Vivo Models of Chronic Myeloid Leukemia (CML).. Blood. 110(11). 1032–1032. 15 indexed citations

Boyce, Brendan F., Lianping Xing, Zhenqiang Yao, et al.. (2006). Future Anti‐Catabolic Therapeutic Targets in Bone Disease. Annals of the New York Academy of Sciences. 1068(1). 447–457. 18 indexed citations

Boyce, Brendan F., Lianping Xing, Zhenqiang Yao, et al.. (2006). Src Inhibitors in Metastatic Bone Disease. Clinical Cancer Research. 12(20). 6291s–6295s. 39 indexed citations

Corbin, Amie S., Shadmehr Demehri, Ian J. Griswold, et al.. (2005). In vitro and in vivo activity of ATP-based kinase inhibitors AP23464 and AP23848 against activation-loop mutants of Kit. Blood. 106(1). 227–234. 47 indexed citations

Corbin, Amie S., Shadmehr Demehri, Ian J. Griswold, et al.. (2004). In Vitro and In Vivo Activity of the Src/Abl Kinase Inhibitor AP23464 and Analogs Against Activation Loop Mutants of KIT.. Blood. 104(11). 793–793. 2 indexed citations

Boyce, Brendan F., Lianping Xing, William C. Shakespeare, et al.. (2003). Regulation of bone remodeling and emerging breakthrough drugs for osteoporosis and osteolytic bone metastases. Kidney International. 63(85). S2–S5. 38 indexed citations

Berger, Carolina, C. Anthony Blau, Meei‐Li Huang, et al.. (2003). Pharmacologically regulated Fas-mediated death of adoptively transferred T cells in a nonhuman primate model. Blood. 103(4). 1261–1269. 49 indexed citations

Sawyer, Tomi K., Brendan F. Boyce, David C. Dalgarno, & John D. Iuliucci. (2001). Src inhibitors: genomics to therapeutics. Expert Opinion on Investigational Drugs. 10(7). 1327–1344. 30 indexed citations

10.

Iuliucci, John D., Stuart Oliver, Steven K. Morley, et al.. (2001). Intravenous Safety and Pharmacokinetics of a Novel Dimerizer Drug, AP1903, in Healthy Volunteers. The Journal of Clinical Pharmacology. 41(8). 870–879. 98 indexed citations

11.

Magari, Shannon R., Victor M. Rivera, John D. Iuliucci, Michael Gilman, & Franklin Cerasoli. (1997). Pharmacologic control of a humanized gene therapy system implanted into nude mice.. Journal of Clinical Investigation. 100(11). 2865–2872. 42 indexed citations

12.

Jonker, Margreet, Koon Y. Pak, Sarah Tam, et al.. (1993). In vivotreatment with a monoclonal chimeric anti-CD4 antibody results in prolonged depletion of circulating CD4+ cells in chimpanzees. Clinical & Experimental Immunology. 93(3). 301–307. 15 indexed citations

13.

Coller, Barry S., L E Scudder, Jürg H. Beer, et al.. (1991). Monoclonal Antibodies to Platelet Glycoprotein IIb/IIIa as Antithrombotic Agentsa. Annals of the New York Academy of Sciences. 614(1). 193–213. 124 indexed citations

14.

Mitala, Joseph, James P. Boardman, Richard A. Carrano, & John D. Iuliucci. (1984). Novel accessory skull bone in fetal rats after exposure to aspirin. Teratology. 30(1). 95–98. 8 indexed citations

15.

Boardman, James P., Joseph Mitala, Richard A. Carrano, & John D. Iuliucci. (1984). Cartilage‐staining technique for the examination of unskinned fetal rat specimens previously processed with alizarin red S. Teratology. 30(3). 383–384. 8 indexed citations

16.

Iuliucci, John D. & Ronald F. Gautieri. (1971). Morphine-Induced Fetal Malformations II: Influence of Histamine and Diphenhydramine. Journal of Pharmaceutical Sciences. 60(3). 420–425. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact